A new study published by the New England Journal of Medicine (NEJM) focused on how effective convalescent plasma had been when treating COVID-19 patients.
In a retrospective study based on a U.S. national registry, these researchers found of the 3,082 patients included in this analysis published on January 13, 2021, death within 30 days after plasma transfusion occurred in (22.3%) of the patients in the high-titer group (27.4%) of the patients in the medium-titer group, and (29.6%) in the low-titer patient group.
Read More
